Implementation Brief: Considerations for developers in applying the Multiple Best Price (MBP) rule to improve access to novel therapies

Eric NormanFoCUS, Research Briefs

This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect … Read More

BioCentury OpEd: Biomedical Innovation Requires Health System Innovation

Eric NormanNews

New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More

BioCentury OpEd: Biomedical Innovation Requires Health System Innovation

Eric NormanArticles

New guest commentary in BioCentury by Gigi Hirsch & Jane Barlow seeds a series of discussions now underway to shape priorities for the “Next Big Thing” in the Center for … Read More

Implementation Brief: Understanding access issues for new therapies

Eric NormanFoCUS, Research Briefs

Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with … Read More

Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform

Eric NormanFoCUS, Publications, Whitepapers

Gene therapies delivered through a single administration have revolutionized treatment possibilities for many patients living with serious or fatal conditions such as spinal muscular atrophy, hemophilia, and sickle cell disease. … Read More

Emerging market solutions for financing and reimbursement of gene therapies for sickle cell disease: Why do payment innovation?

Eric NormanFoCUS, Research Briefs

The FDA has approved two cell and gene therapies for sickle cell disease, marking a significant development for the largest population condition to date. ​ However, the high treatment costs, … Read More